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Abstract 
Aims: Cerebral amyloid angiopathy (CAA) is the accumulation of amyloid beta (Aβ) in the walls of cerebral arte-
rioles, arteries and capillaries. Changes in the white matter in CAA are observed as hyperintensities and dilated 
perivascular spaces on MRI suggesting impairment of fluid drainage but the pathophysiology behind these 
changes is poorly understood. We tested the hypothesis that proteins associated with clearance of Aβ peptides 
are upregulated in the white matter in cases of CAA. 
Methods: In this study, we compare the quantitative proteomic profile of white matter from post-mortem brains 
of patients with CAA and age-matched controls in order to gain insight into the cellular processes and key mole-
cules involved in the pathophysiology of CAA. 
Results: Our proteomic analysis resulted in the profiling of 3,734 proteins (peptide FDR p<0.05). Of these, 189 
were differentially expressed in CAA vs. control. Bioinformatics analysis of these proteins showed significant en-
richment of proteins related to cell adhesion | cell-matrix interaction, mitochondrial dysfunction and hypoxia. 
Upregulated proteins in CAA included EMILIN2, COL4A2, TLN1, CLU, HSPG2. Downregulated proteins included 
DSP, IDE, HBG1. 
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Conclusions: The present study reports an in-depth quantitative proteomic profiling of white matter from pa-
tients with CAA, highlighting extracellular matrix proteins and clusterin as key molecules in the pathophysiology 
of white matter changes in cases of CAA. 
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Abbreviations 
CAA - cerebral amyloid angiopathy, WMH - 
white matter hyperintensities, IPA - Ingenuity path-
way analysis, COL4A2 - Collagen IV alpha 2, HSPG2 - 
heparan sulfate proteoglycan 2, EMILIN2 - EMI Do-
main Endowed, TLN1 - Talin1, CLU - Clusterin, IDE - 
Insulin degrading enzyme, DSP - Desmoplakin, IPAD 
- Intramural Periarterial Drainage 
Introduction 
Cerebral amyloid angiopathy (CAA) is charac-
terized by the deposition of amyloid proteins includ-
ing amyloid beta (Aβ), cystatin C, prion protein, 
ABri/ADan, transthyretin, gelsolin and immuno-
globulin light chain amyloid (1) in the walls of lepto-
menigeal arteries and cortical arterioles (CAA-Type 
2) (2) and in the walls of arteries or capillaries (CAA-
Type 1), but rarely in the walls of venules (1-3). Spo-
radic CAA is a common feature of Alzheimer’s dis-
ease (1-3) and reflects the failure of clearance of 
proteins and interstitial fluid from the ageing brain 
(4, 5). 
Although CAA is uncommon in the white mat-
ter, (6) there are radiological features in the white 
matter in cases of CAA that include white matter hy-
perintensities (WMH) and dilated perivascular 
spaces (7, 8). The underlining pathophysiology is 
poorly understood, but the WMH are associated 
with small vessel disease (9). In addition to damage 
 
 
Figure 1: Outline of experimental workflow. Labelled peptides were analysed using two-dimensional liquid chromatography and tandem 
mass spectrometry. 
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to nerve fibres particularly in the deep white matter, 
the WMH suggest that there is an increase in the vol-
ume of interstitial fluid (ISF) in the affected white 
matter. Pathologically, WMH are characterised by 
pallor of myelin staining in the affected white matter 
with morphological changes in astrocytes and axons 
and disruption of the distribution of aquaporin 4 in 
astrocyte processes (10). Imaging studies in the 
early stages of WMH suggest that the lesions are 
due to altered interstitial fluid mobility and water 
content that may be reversible (11). 
Interstitial fluid and Aβ enter the basement 
membranes of capillaries and arteries to be cleared 
from the brain along the intramural periarterial 
drainage (IPAD) pathways (12, 13). With increasing 
age, the structure of basement membranes changes 
and Aβ accumulates in the walls of arteries as CAA 
(14-16). Our proteomic studies performed on lep-
tomeningeal arteries from brains with CAA demon-
strated an upregulation of clusterin (apolipoprotein 
J) and tissue inhibitors of metalloproteinases 3 
(TIMP3) (17). 
The aim of the present study was to compare 
the quantitative proteomic profile of white matter 
from patients with CAA to the corresponding brain 
region of age-matched controls in order to gain in-
sight in the pathophysiology of white matter 
changes in CAA and to identify novel therapeutic tar-
gets. An overview of the present study workflow is 
presented in Figure 1. 
Materials and methods 
Tissue samples 
Fresh frozen white matter from the occipital 
lobe of severe CAA cases (n=6) and non-demented 
aged matched controls (n=4) was supplied by New-
castle Brain Tissue Resource (Ethics REC 
08/H0906/136) (Table 1). All cases were diagnosed 
according to internationally-used criteria including 
neuritic Braak stages (18), Thal amyloid phases (19), 
and CERAD scores (20) (Table 1). 
Tissue quantitative proteomics analysis 
Samples of 1mg per case were dissolved in 0.5 
M triethylammonium bicarbonate in 0.05% sodium 
dodecyl sulphate. These were then subjected to 
pulsed probe sonication (Misonix, Farmingdale, NY, 
USA) and lysates were centrifuged (16,000 g, 10 min, 
4°C). Supernatants were measured for protein con-
tent using the bicinchoninic acid assay (Pierce BCA 
Protein Assay Kit, Thermo Fisher Scientific, Wal-
tham, MA, US). 100 μg of protein was used per sam-




Table 1: Demographics of the cases used for this study. PM: post-mortem. The PM delay refers to the number of hours post-mortem until 
the tissue was dissected and frozen. 
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reduced with 4μL 50mM Tris(2-carboxyethyl)phos-
phine hydrochloride at 60°C for 1 hour and alkylated 
using 2 μL 200mM methanethiosulfonate at room 
temperature for 10 min. Proteins were enzymati-
cally digested using trypsin overnight in dark at 37°C 
(Sigma Aldrich, St. Louis, MO, USA). Peptides from 
each sample were labelled using the 10plex Tandem 
Mass Tag (TMT) reagent kit (Thermo Fisher Scien-
tific, Waltham, MA, US). Labelled peptides were 
mixed and analyzed using two-dimensional liquid 
chromatography and tandem mass spectrometry as 
reported previously (17). 
Database searching 
Unprocessed raw files were submitted to Pro-
teome Discoverer 1.4 (Thermo Fisher Scientific, Wal-
tham, MA, US) for target decoy search using Se-
quest. The UniProtKB homo sapiens database which 
comprised 20,159 entries (release date January 
2015) was utilized. The search allowed for up to two 
missed cleavages, a precursor mass tolerance of 
10ppm, a minimum peptide length of six and a max-
imum of two variable (one equal) modifications of; 
oxidation (M), deamidation (N, Q), or phosphoryla-
tion (S, T, Y). Methylthio (C) and TMT 6-plex (K, Y and 
N-terminus) were set as fixed modifications. False 
discovery rate (FDR) corrected p value at the peptide 
level was set at <0.05. Percent co-isolation excluding 
peptides from quantitation was set at 50. Reporter 
ion ratios from unique peptides only were taken into 
consideration for the quantitation of the respective 
protein. 
Quantitation per protein in each of the six CAA 
patients was divided by each of the two matched 
same sex controls, which yielded 12 quantitative ra-
tios per protein. These ratios, which represent the 
overall fold change in protein in the CAA patients 
with respect to the controls, were median-normal-
ized and log2 transformed. We then combined the 
two respective log2 ratios per CAA patient when 
compared to the two controls by their mean which 
generated one observation per CAA patient per pro-
tein (see Supplementary Table 1). Due to small sam-
ple size, statistical analysis was performed per pro-
tein regardless of gender (n=6). Based on a previous 
study (16), we set the cut point of log2 ratio higher 
than or equals to 0.6, or lower than or equals to -0.6 
to identify differentially expressed proteins (DEPs) 
(equivalent to a 1.5-fold change), but this was con-
sidered too restrictive for complex structure such as 
the white matter (number of proteins included = 
51). Hence, we have narrowed the gap by halving 
the cut point to ±0.3 (equivalent to 1.2-fold change) 
instead in this study (number of proteins included = 
189). Proteins identified with at least two unique 
peptides were included in the analysis. One-sample 
t test was performed on these log2 ratios per pro-
tein, comparing to 0, to identify the proteins that 
were statistically significant and differentially ex-
pressed in CAA patients comparing to controls (p 
<0.05). 
Bioinformatics analysis 
Ingenuity Pathway Analysis (IPA) (Qiagen, Hil-
den, Germany) and MetaCore (Clarivate Analytics, 
Philadelphia, PA, USA) were used to identify signifi-
cantly enriched processes and pathways in the dif-
ferentially expressed proteins of white matter from 
patients with CAA vs. control. P values in the context 
of canonical pathway analysis reflect how signifi-
cantly the pathway is over-represented in the da-
taset of DEPs in white matter from patients with CAA 
vs. controls. Significance was set at p < 0.05. 
Results 
The global, untargeted proteomic analysis re-
sulted in the profiling of 3,734 proteins (peptide FDR 
p<0.05) (Supplementary Tables 1, 2, 3). Of these, 
189 were differentially expressed in CAA (Supple-
mentary Table 4). 
Bioinformatics analysis of the differentially ex-
pressed proteins (DEPs) using MetaCore showed sig-
nificant enrichment of the cell adhesion | cell-matrix 
interaction process (Figure 2). Mapping on this pro-
cess network, EMILIN-2 (EMILIN2), fibrillin-1 (FBN1), 
collagen alpha-2(IV) (COL4A2) and the extracellular 
protein heparan sulfate proteoglycan (HSPG2) were 
upregulated; inter-alpha trypsin inhibitor heavy 
chain H3 (ITIH3) was downregulated in CAA vs. con-
trol. Figure 3 is a bar graph showing the relative ex-
pression levels of key upregulated (EMILIN2, 
COL4A2, talin-1 (TLN1), clusterin (CLU)) and down-
regulated (desmoplakin (DSP), insulin-degrading en-
zyme (IDE), hemoglobin subunit gamma-1 (HBG1)) 
proteins in the white matter of patients with CAA vs. 
controls (Figure 3).
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Figure 2: Bioinformatics analysis using MetaCore showed significant enrichment of the cell-adhesion | cell-matrix interaction processes 
in the differentially expressed proteins of white matter from patients with CAA vs. controls. Upregulated proteins (EMILIN-2, Fibrillin, 
Collagen IV, Perlecan) are highlighted with a red circle whereas downregulated proteins (ITIH3) with a blue circle. The p represents signif-
icance of enrichment (i.e. this pathway is significantly enriched in the list of differentially expressed proteins). 
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Figure 3: Up-regulated (red) and downregulated (blue) proteins in white matter from patients with CAA vs. controls. A positive log2ratio 
(ratio>1) reflects up- whereas a negative log2ratio (ratio<1) reflects downregulation of the respective protein in patients with CAA vs. 
controls. 
 
MetaCore demonstrated dysregulation of the 
hypoxia-inducible factor 1alpha (HIF1A) in CAA with 
upregulation of diamine acetyltransferase 2 (SAT2) 
and downregulation of heat shock 70kDa protein 4 
(HSPA4), heat shock 70kDa protein 1A/1B (HSPA1A), 
78kDa glucose-related protein (HSPA5), endoplas-
min (HSP90B1), transitional endoplasmic reticulum 
ATPase (VCP) and guanine nucleotide binding pro-
tein subunit beta-2-like-1 (GNB2L1), suggesting al-
tered response to hypoxia in CAA (Figure 4). 
Mitochondrial function also appeared altered 
in CAA with upregulation of the mitochondrial fis-
sion 1 protein (FIS1), a marker of mitochondrial and 
mitophagy (21) and reductions in proteins associ-
ated with the normal function of the mitochondria 
(mitochondrial succinate dehydrogenase flavopro-
tein subunit (SDHA), mitochondrial aconitate hydra-
tase (ACO2), mitochondrial phospholipid hydroper-
oxide glutathione peroxidase (GPX4), mitochondrial 
ATP synthase subunit beta (ATP5F1B), mitochon-
drial thioredoxin reductase 2 (TXNRD2), mitogen-ac-
tivated protein kinase 9 (MAPK9)). Mitochondrial 
dysfunction was a significantly over-represented ca-
nonical pathway (Figure 5).
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Figure 4: Negative regulation of HIF1A was a significantly enriched pathway map in the differentially expressed proteins of white matter 
from patients with CAA vs. controls. Upregulated proteins are highlighted with a red circle whereas downregulated proteins with a blue 
circle. More specifically, SAT2 was upregulated whereas HSP70, HSPA4, HSP90, RACK1 were downregulated in CAA vs. control. The p 
represents significance of enrichment (i.e. this pathway is significantly enriched in the list of differentially expressed proteins). 
Free Neuropathology 1:28 (2020) Antigoni Manousopoulou et al 







Figure 5: Mitochondrial dysfunction was a significantly enriched canonical pathway in the differentially expressed proteins of white matter 
from patients with CAA vs. controls. Upregulated proteins are denoted with red whereas downregulated proteins with blue. More specif-
ically, FIS1 was upregulated whereas SDHA, ACO2, GPX4, ATP5F1B, TXNRD2 and MAPK9 were downregulated in CAA vs. control. The p 
represents significance of enrichment (i.e. this pathway is significantly enriched in the list of differentially expressed proteins). 
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The present study reports a comprehensive 
global proteomic profile of post-mortem white mat-
ter samples from patients with CAA compared to the 
corresponding brain region of age-matched con-
trols. Out of 189 proteins identified as differentially 
expressed with both Metacore and IPA, several pro-
teins associated with mitochondrial dysfunction, hy-
poxia, and clearance of Aβ are significantly up- or 
downregulated. The pathways reflecting hypoxia 
and mitochondrial dysfunction have been observed 
in previous analyses of the white matter in Alz-
heimer’s disease (22). Hypoxia-inducible factor-1 
(HIF1) regulates oxygen homeostasis and thus has a 
major role in the control of energy/metabolism and 
angiogenesis. Diamine-acetyltransferase-2 (SAT2), 
guanine nucleotide binding protein subunit beta-2-
like 1 (GNB2L1) and heat shock proteins are involved 
in the degradation of HIF1 (23, 24) and they were 
expressed at altered levels in the white matter of 
CAA cases (Figure 4). In the present study there was 
an increase in FIS1, a marker of mitochondrial and 
mitophagy (21), and a reduction in proteins associ-
ated with the normal function of the mitochondria 
(SDHA, ACO2, GPX4, ATP5F1B, TXNRD2, MAPK9), 
suggesting an overall dysregulation of the functions 
of the mitochondria in the white matter from cases 
of CAA (Figure 5). 
Most of the novel proteins showing substantial 
changes in the present study of the white matter in 
CAA were proteins associated with the extracellular 
matrix constituents and clearance of Aβ. 
Proteins with increased expression 
Collagen IV alpha 2 chain (COL4A2) is a highly 
conserved protein across species and is present in 
almost all vascular basement membranes (BM) (25). 
A common variation in the COL4A2 gene is associ-
ated with patients with intracerebral haemorrhage 
(26), which is one of the most frequent CAA-related 
cerebrovascular complications. Consistent with the 
current proteomic results, previous studies have re-
ported increased collagen IV expression in cerebral 
microvessels in patients with Alzheimer’s disease 
(27) and increased collagen IV immunostaining in 
the leptomeningeal arteries in hereditary Cystatin C 
amyloid angiopathy (28). A recent proteomic study 
of the grey matter in AD with CAA type 1 (predomi-
nantly capillary CAA) has identified collagen alpha-
2(VI) (COL6A2) as increased in the grey matter of 
CAA Type 1(29). Perlecan is a heparan sulfate prote-
oglycan 2 (HSPG2), also a component of BM and pro-
vides dynamic flexibility to the BM, while promoting 
the aggregation of Aβ (30, 31). Pathological studies 
have reported increased expression of HSPG2 in Alz-
heimer’s disease (32) with a significant association 
of HSPG2 polymorphism in apolipoprotein ε4 allele 
carriers (33). The upregulation of COL4A2 and 
HSPG2 have been observed in other studies in the 
grey matter, but their increase in the white matter 
of CAA cases in the present study demonstrate the 
widespread changes in the extracellular matrix in 
the brain, reflected in a failure of intramural peri-
arterial drainage (IPAD). 
EMILIN-2 was expressed at higher levels in the 
white matter from brains with CAA vs. controls. 
EMILIN-2 is part of the EDEN (EMI Domain EN-
dowed) spectrum of proteins (34), with roles in an-
giogenesis, as well as cell adhesion/migration (34, 
35). EMILIN-2 possesses the gC1q domain, which in-
teracts with α4β1 integrin, which in turn binds to fi-
bronectin, a major component of BM (36). Recent 
studies demonstrated a reduction in fibronectin in 
post-mortem brains with white matter hyperinten-
sities as well as on cerebrovascular smooth muscle 
cell cultures exposed to hypercapnia as a model of 
hypoperfusion (37). Although the expression of 
EMILIN-2 in brain is relatively small compared to 
other organs and the physiological role of EMILIN-2 
is unclear (38), its association with BM (39) suggests 
that the upregulation of EMILIN-2 reflects a com-
pensatory upregulation of angiogenesis and IPAD in 
the face of the hypoperfusion and altered extracel-
lular matrix characteristics of the white matter in 
CAA (15, 40). 
Talin-1 (TLN1) is a heavy protein that contains 
a C-terminal flexible rod domain which binds to vin-
culin and actin while the N-terminal head binds to 
integrin cytoplasmic tails (41-43). Binding of the talin 
head to integrin is a key step required for integrin 
activation (44, 45). Integrins are essential for cell ad-
hesion and α5β1 is anti-apoptotic and a receptor for 
Aβ (46). As talin also promotes axon growth (47), it 
is possible that it is upregulated as a compensatory 
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effect of axonal and synapse destruction in white 
matter lesions (22). 
In the present study, the expression of CLU 
(clusterin) was higher in the white matter of CAA 
cases compared to controls. Our own prior proteo-
mic study of leptomeningeal arteries in CAA re-
vealed a high expression of CLU, and a recent study 
on the proteomic expression of grey matter in CAA 
also revealed an increased expression of CLU (17). 
Genome-wide association studies identified varia-
tions in CLU expression associated with Alzheimer’s 
disease (48, 49). Clusterin may act as a chaperone 
molecule that facilitates intramural periarterial 
drainage of soluble Aβ (50). Increased expression of 
CLU may be a compensatory mechanism to the cer-
ebrovascular accumulation of Aβ in these cases. 
Proteins with decreased expression 
IDE (Insulin-degrading enzyme) was signifi-
cantly decreased in our study. IDE is a key enzyme 
that degrades Aβ in the extracellular spaces (51). In 
diabetes mellitus there is inhibition of Aβ degrada-
tion directly associated with a reduced activity of IDE 
(52-54). Overexpression of IDE ameliorates Aβ pa-
thology (55). IDE is expressed within the vessel walls 
and its activity is decreased in CAA (56). The de-
creased expression of IDE may reflect a failure of the 
proteolysis and consequent increased toxicity of Aβ. 
The expression of HBG1, the γ(A)-globin subu-
nit of fetal haemoglobin, was also decreased in our 
study. HBG1 is capable of strongly binding to Aβ 
(57). An animal model of CAA exhibited impaired Aβ 
transcytosis from brain to blood, resulting in de-
creased level of Aβ in the blood (58). Decreased ex-
pression of HBG1 may result from reduced level of 
the Aβ and HBG1 complex in the blood in cases of 
CAA. 
Desmoplakin (DSP) is a desmosome-associated 
transmembrane glycoprotein and maintains the in-
tegrity of the epidermis and myocardium (59). The 
physiological role of desmoplakin in the brain re-
mains unknown. Interestingly, it was reported that 
desmoplakin is a specific marker of lymphatic ves-
sels in human tongue (60). Since IPAD represents the 
lymphatic drainage pathways of the brain paren-
chyma, (61) a decreased level of desmoplakin may 
simply reflect impaired IPAD. 
The present study has some limitations: Firstly, 
the sample size is low due to the difficulty in obtain-
ing fresh frozen white matter. This has also pre-
vented us from performing an analysis by sex or any 
other stratification. Secondly, it was not possible to 
specifically select areas of WMH from the frozen 
samples of brain and to study them separately. Nev-
ertheless, our study has revealed generalised 
changes in the white matter in cases of CAA. Thirdly, 
we have not performed validation of the results by 
immunocytochemistry for the proteins involved. 
However, we have provided evidence from other 
studies that support our findings and provide a 
working hypothesis. 
While previous proteomic studies in the white 
matter in Alzheimer’s disease have identified modi-
fications in proteins that are involved in cell survival 
and cell adhesion (22), in our study, we highlight 
that in the white matter of severe cases of CAA there 
is upregulation of the proteins that mark cell-matrix 
interaction, hypoxia, mitochondrial dysfunction and 
intramural periarterial drainage of soluble Aβ. 
The study from Castano et al in 2013 used AD 
cases with a very low CAA score (2 out of a maximum 
of 12) and identified GFAP, tropomyosins, calmodu-
lin, annexin 1 and alpha-internexin as significantly 
upregulated, while ubiquitin carboxyl-terminal es-
terase and fascin-1 were down-regulated (22). The 
upregulated proteins are part of the cytoskeleton 
maintenance, calcium metabolism and cell survival 
pathways. We also have identified annexin and ubiq-
uitin carboxyl-terminal esterase modified in the 
same pattern. The different results between the two 
studies are likely to be due to the very different CAA 
status of the cases; the present study points to path-
ways that are involved in the clearance of Aβ along 
the vessel walls. 
Our results suggest a working hypothesis that 
there is upregulation of the intramural periarterial 
drainage (IPAD) pathways in the white matter as a 
compensatory mechanism to the failure of drainage 
of interstitial fluid and solutes from the white matter 
and the grey matter that is a key pathogenetic factor 
in CAA. 
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